Quantcast
Last updated on April 16, 2014 at 12:26 EDT

Latest Protein-bound paclitaxel Stories

2008-07-14 09:00:14

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced it has received approval from the China State Food and Drug Administration to market ABRAXANE(R) Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S. and China on which this approval was based demonstrated that ABRAXANE...

2006-10-30 18:00:29

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company today announced the launch of the Abraxis Patient Access Program (APAP), a comprehensive patient assistance program for cancer patients being treated with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Through APAP, financially eligible cancer patients in need of treatment with ABRAXANE will receive access to the drug at no cost. This new...

2006-04-27 02:15:07

LONDON (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it had agreed to sell its U.S. anesthetics and analgesic product portfolio to Abraxis BioScience for $350 million. AstraZeneca said it had also agreed to buy the rights to co-promote breast cancer drug Abraxane in the United States from Abraxis BioScience for $200 million. Europe's third-biggest drugmaker, due to report first-quarter results at 0900 GMT, said the two deals would have a broadly neutral impact...